IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	DOI et al.	Examiner:	Unassigned
Application No.:	10/526,234	Group Art Unit:	Unassigned
Filed:	February 28, 2005	Confirmation No.:	Unassigned
Docket No.:	3190-072	Customer No.:	33432

For: METHOD OF DEGRADATION, METHOD FOR INHIBITING DEGRADATION, AND AGENT FOR INHIBITING DEGRADATION, FOR TRANSCRIPTION FACTORS OF GLUCOSE METABOLISM-RELATED GENES (as amended)

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR 1.97(b)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

May 23, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Information Disclosure Statement is being submitted before expiration of the three-month period following filing of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. *See* 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application,

and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925.

Respectfully submitted,



Luke A. Kilyk
Reg. No. 33,251

Atty. Docket No.: 3190-072
KILYK & BOWERSOX, P.L.L.C.
53 A East Lee Street
Warrenton, VA 20186
Tel.: (540) 428-1701
Fax: (540) 428-1720
Enclosures: PTO-1449, w/44 Documents

FORM PTO-1449 (RE[illegible]-80)	Atty. Docket No. 3190-072	Application No. 10/526,234
INFORMATION DISCLOSURE STATEMENT	APPLICANT: DOI et al.	
	Filing Date: February 28, 2005	Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE, IF APPROPRIATE
		2004/0121398 A1	6/24/04	Doi et al.	435	7.1	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Copy of International Preliminary Examination Report for PCT/JP2003/011046 dated July 29, 2004 (English translation).
	Shih et al., "Dissecting the Transcriptional Network of Pancreatic Islets During Development and Differentiation," PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, Vol. 98, No. 25, December 4, 2001 (pp. 14189-14191).
	Sturges et al., "Calcium-dependent Inactivation of RNA Polymerase III Transcription," THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 269, No. 8, February 25, 1994 (pp. 5712-5719).
	Watt et al., "Specific Cleavage of Transcription Factors by the Thiol Protease, M-Calpain," NUCLEIC ACIDS RESEARCH, Vol. 21, No. 22, 1993 (pp. 5092-5100).
	Sasaki et al., "Comparative Specificity and Kinetic Studies on Porcine Calpain I and Calpain II with Naturally Occurring Peptides and Synthetic Fluorogenic Substrates," THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 259, No. 20, October 25, 1984 (pp. 12489-12494).
	Sorimachi, "Structure and Function of Calpain and Its Homologues," SEIKAGAKU, Vol. 72, No. 11, November 25, 2000 (pp. 1297-1315) (with partial English translation).
	Huang et al., "The Calpain Family and Human Disease," TRENDS IN MOLECULAR MEDICINE, Vol. 7, No. 8, August 2001 (pp. 355-362).
	Matsushima-Nishiwaki et al., "Limited Degradation of Retinoid X Receptor by Calpain," BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 225, No. 1276, 1996 (pp. 946-951).
	Pariat et al., "Proteolysis by Calpains: a Possible Contribution to Degradation of p53," MOLECULAR AND CELLULAR BIOLOGY, Vol. 17, No. 5, May 1997 (pp. 2806-2815).
	Ravid et al., "The Ubiquitin-Proteasome Pathway Mediates the Regulated Degradation of Mammalian 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase," THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 275, No. 46, November 17, 2000 (pp. 35840-35847).
	Debiasi et al., "Reovirus-Induced Apoptosis is Proceded by Increased Cellular Calpain Activity and is Blocked by Calpain Inhibitors," JOURNAL OF VIROLOGY, Vol. 73, No. 1, January 1999 (pp. 695-701).
	Dutt et al. "*m*-Calpain Subunits Remain Associated in the Presence of Calcium," FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES, Vol. 436, 1998 (pp. 367-371).

FORM PTO-1449 (REV 7-80)	Atty. Docket No. 3190-072	Application No. 10/526,234
INFORMATION DISCLOSURE STATEMENT	APPLICANT: DOI et al.	
	Filing Date: February 28, 2005	Group Art Unit: Unassigned

	Esser et al., "Cysteine Proteinase Inhibitors Decrease Articular Cartilage and Bone Destruction in Chronic Inflammatory Arthritis," ARTHRITIS & RHEUMATISM, Vol. 37, No. 2, February 1994 (pp. 236-247).
	Sasaki et al., "Inactivation of Calpain I and Calpain II by Specificity-Oriented Tripeptidyl Chloromethyl Ketones," JOURNAL OF BIOCHEMISTRY, Vol. 99, No. 1, 1986 (pp. 173-179).
	Nath et al., "Processing of cdk5 Activator p35 to Its Truncated Form (p25) by Calpain in Acutely Injured Neuronal Cells," BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 274, 2000 (pp. 16-21).
	Brooks et al., "Effect of Alloxan Diabetes on a Ca^{2+} -activated Proteinase in Rat Skeletal Muscle," AMERICAN JOURNAL OF PHYSIOLOGY, Vol. 244, No. 3, 1983 (pp. C175-C181).
	Kobayashi et al., "Diabetic State-Induced Activation of Calcium-Activated Neutral Proteinase in Mouse Skeletal Muscle," ENDOCRINOLOGIA JAPONICA, Vol. 36, No. 6, 1989 (pp. 833-844).
	Sreenan et al., "Calpains Play a Role in Insulin Secretion and Action," DIABETES, Vol. 50, September 2001 (pp. 2013-2020).
	Horikawa et al., "Genetic Variation in the Gene Encoding Calpain-10 is Associated with Type 2 Diabetes Mellitus," NATURE GENETICS, Vol. 26, October 2000 (pp. 163-175).
	Baier et al., "A Calpain-10 Gene Polymorphism is Associated with Reduced Muscle mRNA Levels and Insulin Resistance," THE JOURNAL OF CLINICAL INVESTIGATION, Vol. 106, 2000 (pp. R69-R73).
	Yanese, "Obesity and Transcription Factors," BIO CLINICA, Vol. 12, No. 5, 2002, (pp. 410-414) (with partial English translation).
	Stoffel et al., "The Maturity-Onset Diabetes of the Young (MODY1) Transcription Factor HNF4α Regulates Expression of Genes Required for Glucose Transport and Metabolism," PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, Vol. 94, November 1997 (pp. 13209-13214).
	Shih et al., "Loss of HNF-1α Function in Mice Leads to Abnormal Expression of Genes Involved in Pancreatic Islet Development and Metabolism," DIABETES, Vol. 50, November 2001 (pp. 2472-2480).
	Ban et al., "Hepatocyte Nuclear Factor-1α Recruits the Transcriptional Co-Activator p300 on the GLUT2 Gene Promoter," DIABETES, Vol. 51, May 2002 (pp. 1409-1418).
	Cha et al., "HNF1 and/or HNF3 May Contribute to the Tissue Specific Expression of Glucokinase Gene," EXPERIMENTAL AND MOLECULAR MEDICINE, Vol. 33, No. 2, June 2001 (pp. 59-63).
	Bartoov-Shifman et al., "Activation of the Insulin Gene Promoter Through a Direct Effect of Hepatocyte Nuclear Factor 4α," THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 277, No. 29, July 19, 2002 (pp. 25914-25919) (with copy of document as published online May 6, 2002).
	Ryffel, "Mutations in the Human Genes Encoding the Transcription Factors of the Hepatocyte Nuclear Factor (HNF)1 and HNF4 Families: Functional and Pathological Consequences," JOURNAL OF MOLECULAR ENDOCRINOLOGY, Vol. 27, 2001 (pp. 11-29).
	Iwasaki, "Diabetes Mellitus," JAPANESE JOURNAL OF CLINICAL PATHOLOGY, Vol. 29, No. 2, 2001 (pp. 161-164) (with English abstract).
	Gragnoli et al., "Maturity-Onset Diabetes of the Young Due to a Mutation in the Hepatocyte Nuclear Factor-4α Binding Site in the Promoter of the Hepatocyte Nuclear Factor-1α Gene," DIABETES, Vol. 46, September 1997 (pp. 1648-1651).
	Sladek et al., "Hepatocyte Nuclear Factor 4α," NUCLEAR RECEPTORS AND GENETIC DISEASE, Chapter 9, 2001 (pp. 309-361).
	Reunen et al., "Disruption of a Binding Site for Hepatocyte Nuclear Factor 4 Results in Hemophilia B Leyden," PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, Vol. 89, July 1992 (pp. 6300-6303).

FORM PTO-1449 (REV. 7-80)	Atty. Docket No. 3190-072	Application No. 10/526,234
INFORMATION DISCLOSURE STATEMENT	APPLICANT: DOI et al.	
	Filing Date: February 28, 2005	Group Art Unit: Unassigned

	Carew et al., "A New Mutation in the HNF4 Binding Region of the Factor VII Promoter in a Patient with Severe Factor VII Deficiency," BLOOD, Vol. 96, No. 13, December 15, 2000 (pp. 4370-4372).
	Okita et al., "Human Insulin Gene is a Target Gene of Hepatocyte Nuclear Factor-1α (HNF-1α) and HNF-1β," BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 263, 1999 (pp. 566-569).
	Wang et al., "Dominant-Negative Suppression of HNF-1α Function Results in Defective Insulin Gene Transcription and Impaired Metabolism-Secretion Coupling in a Pancreatic β-Cell Line," THE EMBO JOURNAL, Vol. 17, No. 22, 1998 (pp. 6701-6713).
	Yamagata et al., "Mutations in the Hepatocyte Nuclear Factor-1α Gene in Maturity-Onset Diabetes of the Young (MODY3)," NATURE, Vol. 384, December 5, 1996 (pp. 455-458).
	Bluteau et al., "Bi-allelic Inactivation of TCF1 in Hepatic Adenomas," NATURE GENETICS, Vol. 32, October 2002 (pp. 312-315).
	Pontoglio et al., "Hepatocyte Nuclear Factor 1 Inactivation Results in Hepatic Dysfunction, Phenylketonuria, and Renal Fanconi Syndrome," CELL, Vol. 84, February 23, 1996 (pp. 575-585).
	Thomas et al., "A Distant Upstream Promoter of the HNF-4α Gene Connects the Transcription Factors Involved in Maturity-Onset Diabetes of the Young," HUMAN MOLECULAR GENETICS, Vol. 10, No. 19, 2001 (pp. 2089-2097).
	Waeber et al., "Transcriptional Activation of the GLUT2 Gene by the IPF-1/STF-1/IDX-1 Homeobox Factor," MOLECULAR ENDOCRINOLOGY, Vol. 10, No. 11, 1996 (pp. 1327-1334).
	Ohlsson et al., "IPF1, a Homeodomain-Containing Transactivator of the Insulin Gene," THE EMBO JOURNAL, Vol. 12, No. 11, 1993, (pp. 4251-4259).
	Watada et al., "The Human Glucokinase Gene β-Cell-Type Promoter -- An Essential Role of Insulin Promoter Factor 1/PDX-1 in its Activation in HIT-T15 Cells," DIABETES, Vol. 45, November 1996 (pp. 1478-1488).
	Stoffers et al., "Early-Onset Type-II Diabetes Mellitus (MODY4) Linked to IPF1," NATURE GENETICS, Vol. 17, October 1997 (pp. 138-141).
	Björklund et al., "Glucose-Induced $[Ca^{2+}]_i$ Abnormalities in Human Pancreatic Islets -- Important Role of Overstimulation," DIABETES, Vol. 49, November 2000 (pp. 1840-1848).
	Maruyama et al., "Molecular Interactions Between Presenilin and Calpain: Inhibition of M-Calpain Protease Activity by Presenilin-1, 2 and Cleavage of Presenilin-1 by m-, μ-Calpain," INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, Vol. 5, 2000 (pp. 269-273).

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.